Which adverse event is listed for new GLP-1 receptor agonists?

Which adverse event is listed for new GLP-1 receptor agonists?

• A. Acute kidney injury
• B. Pancreatitis
• C. GI upset
• D. Medullary thyroid carcinoma

Answer: (B)

GLP-1 receptor agonists have a safety signal for pancreatitis. Product labeling for this drug class lists pancreatitis as a potential adverse event and advises clinicians to consider pancreatitis in patients with persistent, severe abdominal pain, with appropriate evaluation and discontinuation if pancreatitis is suspected. This risk has been observed in postmarketing reports and clinical trials, which is why it’s highlighted in labeling as a serious adverse event to watch for. GI upset is indeed common with these agents, but it’s a frequent, expected side effect rather than a listed serious adverse event. Acute kidney injury can occur in the setting of dehydration, but it isn’t a primary labeled adverse event for this class. Medullary thyroid carcinoma is addressed in labeling as a contraindication or caution (not a typical adverse event), given concerns from animal data and human risk considerations.

GLP-1 receptor agonists have a safety signal for pancreatitis. Product labeling for this drug class lists pancreatitis as a potential adverse event and advises clinicians to consider pancreatitis in patients with persistent, severe abdominal pain, with appropriate evaluation and discontinuation if pancreatitis is suspected. This risk has been observed in postmarketing reports and clinical trials, which is why it’s highlighted in labeling as a serious adverse event to watch for.

GI upset is indeed common with these agents, but it’s a frequent, expected side effect rather than a listed serious adverse event. Acute kidney injury can occur in the setting of dehydration, but it isn’t a primary labeled adverse event for this class. Medullary thyroid carcinoma is addressed in labeling as a contraindication or caution (not a typical adverse event), given concerns from animal data and human risk considerations.